Correction to: Nature Communications https://doi.org/10.1038/s41467-025-59184-5, published online 25 April 2025
In this article the Competing Interests statement was incorrectly given as ‘Yong Wang, Yingfei Wang, and W.L. are inventors on provisional patent application US 63/676,270. F.B.-M. has filed patents, including PCT/EP2022/086493, PCT/EP2023/060810, EP23382703 and EP23383369. The other authors declare no competing interests.’ but should have been ‘Yong Wang, Yingfei Wang, and W.L. are inventors on provisional patent application US 63/676,270. F.B.-M. has filed patents including PCT/EP2022/086493, PCT/EP2023/060810, EP23382703 and EP23383369. A.P. reports stockholder and consultant roles at Reveal Genomics, advisory role for Roche, AstraZeneca, Novartis, and Daiichi-Sankyo, and grant funding from Roche, AstraZeneca, Novartis, and Daiichi-Sankyo. C.L.A. serves as scientific advisor to Novartis, Lilly, Merck, Daiichi Sankyo, OrigiMed, Sanofi, AstraZeneca, PUMA Biotechnology, TAIHO Oncology, Arvinas, Athenex, Laekna Therapeutics, and the Susan G. Komen Foundation, and has received research grant support from Pfizer, Lilly, and Takeda. None of these activities are related or relevant to the work presented herein. The other authors declare no competing interests.’. The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Wang, Y., Wang, Y., Bao, L. et al. Publisher Correction: ZMYND8 drives HER2 antibody resistance in breast cancer via lipid control of IL-27. Nat Commun 16, 4769 (2025). https://doi.org/10.1038/s41467-025-60137-1
Published:
Version of record:
DOI: https://doi.org/10.1038/s41467-025-60137-1
